throbber
Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 1 of 18
`
`UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF COLUMBIA
`
`
`
`
`
`
`
`
`
`
`
`Civil Action No.:
`
`
`Judge:
`
`
`UNITED STATES OF AMERICA
`U.S. Department of Justice
`Antitrust Division
`450 Fifth Street, N.W., Suite 8700
`Washington, DC 20530,
`
`Plaintiff,
`
`
`v.
`
`STONE CANYON INDUSTRIES HOLDINGS
`LLC
`1875 Century Park East, Suite 320
`Los Angeles, CA 90067,
`
`SCIH SALT HOLDINGS INC.
`10995 Lowell Avenue, Suite 500
`Overland Park, KS 66210,
`
`K+S AKTIENGESELLSCHAFT
`Bertha-von-Suttner-Str. 7
`34131 Kassel, Hesse
`Germany,
`
`
`and
`
`MORTON SALT, INC.
`444 West Lake Street, Suite 300
`Chicago, IL 60606,
`
`
`Defendants.
`
`COMPLAINT
`
`The United States of America (“United States”), acting under the direction of the
`
`
`
`
`
`
`
`
`
`
`Attorney General of the United States, brings this civil antitrust action against Defendants Stone
`
`Canyon Industries Holdings LLC (“Stone Canyon”), SCIH Salt Holdings Inc. (“SCIH”), K+S
`
`Aktiengesellschaft (“K+S AG”), and Morton Salt, Inc. (“Morton”) to enjoin SCIH’s proposed
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 2 of 18
`
`acquisition of assets including Morton from K+S AG. The United States complains and alleges
`
`as follows:
`
`I.
`
`NATURE OF THE ACTION
`
`1.
`
`Pursuant to a Transaction Agreement dated October 5, 2020, SCIH intends to
`
`acquire assets including Morton from K+S AG for approximately $3.2 billion. As a result of the
`
`acquisition, SCIH would control both Morton and US Salt, which are the largest suppliers of
`
`certain evaporated salt products in the United States.
`
`2.
`
`Together, Morton and US Salt would have a monopoly in the United States and
`
`Canada for pharmaceutical-grade salt, the purest grade of evaporated salt, which is used to make
`
`life-saving treatments and products for patients in need of dialysis fluid, intravenous saline
`
`solution, or other medical products.
`
`3.
`
`Additionally, Morton and US Salt are two of only three companies that supply
`
`U.S. households with “round-can” table salt, a type of evaporated salt that is sold in 26-ounce
`
`round containers with a metal spout and used to flavor food.
`
`4.
`
`Morton and US Salt are also two of only three major suppliers in the northeastern
`
`United States of bulk evaporated salt, which is used by food processors and chemical
`
`manufacturers to make pre-packaged food and everyday cleaning products.
`
`5.
`
`Today, customers benefit from competition between Morton and US Salt in the
`
`form of lower prices, higher quality products, and/or improved service. The proposed
`
`transaction would eliminate this competition, driving the opposite result: higher prices, lower
`
`quality products, and poorer service for customers of pharmaceutical-grade salt in the United
`
`States and Canada, for customers of round-can table salt in the United States, and for customers
`
`of bulk evaporated salt in the northeastern United States.
`
`2
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 3 of 18
`
`6.
`
`Accordingly, SCIH’s acquisition of Morton would violate Section 7 of the
`
`Clayton Act, 15 U.S.C. § 18, and should be enjoined.
`
`II.
`
`THE PARTIES AND THE TRANSACTION
`
`7.
`
`K+S AG is a chemical company headquartered in Kassel, Germany. In 2020,
`
`K+S AG reported revenues of approximately $4.4 billion. K+S AG’s Operating Unit Salt
`
`Americas business includes Morton as well as K+S Windsor Salt, which sells salt products in
`
`Canada, and Sociedad Punta de Lobos, which sells salt products in Chile.
`
`8.
`
`Morton is a K+S AG subsidiary with approximately $1 billion in revenue in 2020.
`
`Morton is the largest supplier of pharmaceutical-grade salt in the United States and Canada, the
`
`largest supplier of round-can table salt in the United States, and one of only three suppliers of
`
`bulk evaporated salt in the northeastern United States.
`
`9.
`
`Stone Canyon is an industrial holding company incorporated in Delaware and
`
`headquartered in Los Angeles, California. Stone Canyon acquired Kissner Group Holdings LP,
`
`which it later renamed SCIH, in April 2020.
`
`10.
`
`SCIH is a subsidiary of Stone Canyon and is headquartered in Overland Park,
`
`Kansas. In 2020, SCIH had revenues of approximately $1 billion. SCIH is a leading supplier of
`
`salt products, including evaporated salt.
`
`11.
`
`US Salt, a subsidiary of SCIH with approximately $95 million in revenues in
`
`2020, is the nation’s second-largest supplier of pharmaceutical-grade salt in the United States
`
`and Canada, the second-largest supplier of round-can table salt in the United States, and one of
`
`only three suppliers of bulk evaporated salt in the northeastern United States.
`
`3
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 4 of 18
`
`12.
`
`Pursuant to a Transaction Agreement dated October 5, 2020, SCIH agreed to
`
`acquire K+S AG’s Operating Unit Salt Americas business, including Morton, for approximately
`
`$3.2 billion.
`
`III.
`
`JURISDICTION AND VENUE
`
`13.
`
`The United States brings this action under Section 15 of the Clayton Act, 15
`
`U.S.C. § 25, to prevent and restrain Defendants from violating Section 7 of the Clayton Act, 15
`
`U.S.C. § 18.
`
`14.
`
`Defendants’ activities substantially affect interstate commerce. Defendants sell
`
`pharmaceutical-grade salt and round-can table salt throughout the United States and bulk
`
`evaporated salt throughout the northeastern United States. This Court has subject matter
`
`jurisdiction over this matter pursuant to Section 15 of the Clayton Act, 15 U.S.C. § 25, and 28
`
`U.S.C. §§ 1331, 1337(a), and 1345.
`
`15.
`
`Defendants have consented to venue and personal jurisdiction in this judicial
`
`district. Venue is proper under Section 12 of the Clayton Act, 15 U.S.C. § 22, and 28 U.S.C. §
`
`1391(b) and (c)(2), for Stone Canyon, SCIH, and Morton, and venue is proper for K+S AG, a
`
`German corporation, under 28 U.S.C. § 1391(c)(3).
`
`IV. RELEVANT MARKETS
`
`A.
`
`Relevant Product Markets
`
`16. Morton and SCIH’s US Salt subsidiary both produce and sell evaporated salt.
`
`Evaporated salt is a type of sodium chloride produced through “vacuum evaporation.” In the
`
`vacuum evaporation process, water is pumped into a salt deposit where the salt dissolves, and the
`
`resulting brine is forced into an evaporator on the surface where it is boiled in a series of pans
`
`until only the salt remains. Evaporated salt is nearly 100% sodium chloride and contains almost
`
`4
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 5 of 18
`
`no other trace minerals. Because of the evaporation process, individual grains of evaporated salt
`
`are also more consistent and regularly shaped than other forms of salt.
`
`17.
`
`Evaporated salt is distinct from salt created through other production methods,
`
`such as rock salt and solar salt. Rock salt is mined and then crushed into smaller sizes before
`
`being transported to the surface. Rock salt is less expensive to produce than evaporated salt, but
`
`it is also coarser, irregularly shaped, and contains other minerals and impurities. As a result,
`
`rock salt is used for applications that have less demanding quality requirements such as de-icing
`
`roads. Solar salt is created when salt water is captured in shallow ponds where the sun
`
`evaporates most of the water. It can only be produced in warm climates where the evaporation
`
`rate exceeds the precipitation rate. Solar salt is less pure and not as uniform in shape as
`
`evaporated salt, but it is purer than rock salt. Solar salt is used for applications such as water
`
`softening.
`
`18.
`
`Evaporated salt typically is used in applications that require the highest quality of
`
`salt, such as human consumption. There are different types of evaporated salt that have different
`
`characteristics, end uses, and customers. Three types of evaporated salt produced by Defendants
`
`constitute relevant product markets—pharmaceutical-grade salt, round-can table salt, and bulk
`
`evaporated salt.
`
`i.
`
` Pharmaceutical-Grade Salt
`
`19.
`
`Pharmaceutical-grade salt is the grade of salt with the highest percentage of
`
`sodium chloride and thus is the purest grade of evaporated salt. Pharmaceutical-grade salt is
`
`used in the pharmaceutical industry as a building block for a number of life-saving treatments
`
`and products, including dialysis fluid, intravenous saline solution, and other medical products.
`
`Pharmaceutical-grade salt must be evaporated from salt deposits of extremely high purity and
`
`5
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 6 of 18
`
`then undergo post-production processing to ensure that it contains virtually no trace minerals or
`
`other impurities.
`
`20.
`
`Because of these stringent standards, the mining and production process for
`
`pharmaceutical-grade salt must be extensively monitored and documented to ensure purity and
`
`consistency across production batches. This documentation must then be provided to customers
`
`as a validation of the quality and purity of the pharmaceutical-grade salt.
`
`21.
`
`Rock salt and solar salt do not meet the purity requirements for pharmaceutical-
`
`grade salt. Other grades of evaporated salt—for example, salt used in food processing—also
`
`cannot serve as a substitute for pharmaceutical-grade salt. Pharmaceutical-grade salt must
`
`contain a higher percentage of sodium chloride than other types of evaporated salt. This ensures
`
`that it does not contain trace minerals that would impact the efficacy of pharmaceutical products
`
`made using pharmaceutical-grade salt. Pharmaceutical-grade salt also cannot contain additives
`
`such as anti-caking agents that are added during the processing of other types of evaporated salt.
`
`Because of these requirements, pharmaceutical-grade salt is more difficult to produce than other
`
`forms of evaporated salt.
`
`22.
`
`In the event of a small but significant increase in price by a hypothetical
`
`monopolist of pharmaceutical-grade salt, substitution away from pharmaceutical-grade salt
`
`would be insufficient to render the price increase unprofitable. Pharmaceutical-grade salt is
`
`therefore a line of commerce, or relevant product market, for purposes of analyzing the effects of
`
`the acquisition under Section 7 of the Clayton Act, 15 U.S.C. § 18.
`
`ii.
`
`Round-Can Table Salt
`
`23.
`
`Table salt is evaporated salt that is processed for human consumption. It is
`
`regulated by the Food and Drug Administration (“FDA”) and must meet high purity standards.
`
`6
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 7 of 18
`
`Table salt also has a highly consistent size across granules and contains agents to prevent
`
`clumping and evaporation. Without additional processing—which raises price considerably—
`
`rock salt and solar salt cannot meet the same purity requirements or achieve the same consistent
`
`granule size as table salt. Pharmaceutical-grade salt meets the purity requirements for table salt
`
`but does not contain the necessary agents to prevent clumping and evaporation. As such, rock
`
`salt, solar salt, and pharmaceutical-grade salt are not substitutes for table salt.
`
`24.
`
`In the United States, the packaging format strongly preferred by consumers for
`
`table salt is the round can, which is a 26-ounce cardboard cylinder with a paper label and a metal
`
`spout. The round-can’s size, shape, material, and metal spout make it an easy receptacle to use
`
`one-handed without spilling while cooking or refilling a salt shaker, which is a product
`
`characteristic that is highly valued by consumers. Reflecting consumer preference, retailers like
`
`grocery stores dedicate shelf space specifically to round-can packaging. As a result,
`
`approximately 95% of the table salt sold to consumers in the United States is sold in a round can.
`
`25.
`
`Table salt packaged in other containers, such as boxes or bags, is not a reasonable
`
`substitute for round-can table salt. Boxes without a metal spout and bags are more difficult to
`
`use and store and may spill once opened. Larger packages of table salt also are not reasonable
`
`substitutes for round-can table salt, as they contain significantly more salt than an individual can
`
`practically use.
`
`26.
`
`In the event of a small but significant increase in price by a hypothetical
`
`monopolist of round-can table salt, substitution away from round-can table salt would be
`
`insufficient to render the price increase unprofitable. Round-can table salt is therefore a line of
`
`7
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 8 of 18
`
`commerce, or relevant product market, for purposes of analyzing the effects of the acquisition
`
`under Section 7 of the Clayton Act, 15 U.S.C. § 18.
`
`iii.
`
`Bulk Evaporated Salt
`
`27.
`
`Bulk evaporated salt is salt that is of sufficient purity to be used for human
`
`consumption that is sold in bulk form. Bulk evaporated salt is used to manufacture chemicals
`
`necessary to create essential everyday cleaning products such as disinfectants, soap, and bleach.
`
`Bulk evaporated salt is also an essential ingredient in nearly all processed pre-packaged foods,
`
`such as sauces, chips and other snacks, and frozen meals. Because bulk evaporated salt is
`
`incorporated into products end-consumers ingest or touch, it is regulated by the FDA and must
`
`meet stringent purity requirements.
`
`28.
`
`Customers for bulk evaporated salt include chemical companies and large pre-
`
`packaged food manufacturers as well as smaller customers, such as bakeries, that use salt as an
`
`essential ingredient in their food products. To accommodate these customers, many of whom
`
`purchase thousands of tons of salt per year, evaporated salt is sold in bulk, by the truckload or in
`
`containers ranging from 50-pound bags to 2,000-pound “super-sacks.”
`
`29.
`
`Bulk evaporated salt is distinct from evaporated salt used for other applications.
`
`Compared to other types of evaporated salt, it has unique end-uses, customers, and packaging.
`
`While pharmaceutical-grade salt and round-can table salt are of sufficient purity, they are priced
`
`too high and packaged in quantities that are too small to serve as substitutes for bulk evaporated
`
`salt. Bulk evaporated salt also is distinct from rock salt and solar salt, which have lower purity
`
`8
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 9 of 18
`
`levels and non-uniform textures that make them unsuitable for chemical and food-production end
`
`uses. None of these types of salt can serve as a substitute to bulk evaporated salt.
`
`30.
`
`In the event of a small but significant increase in price by a hypothetical
`
`monopolist of bulk evaporated salt, substitution away from bulk evaporated salt would be
`
`insufficient to render the price increase unprofitable. Bulk evaporated salt is therefore a line of
`
`commerce, or relevant product market, for purposes of analyzing the effects of the acquisition
`
`under Section 7 of the Clayton Act, 15 U.S.C. § 18.
`
`B.
`
`Relevant Geographic Markets
`
`i.
`
`Pharmaceutical-Grade Salt
`
`31.
`
`Pharmaceutical-grade salt is manufactured in only a few locations in the United
`
`States. From these locations, pharmaceutical-grade salt is shipped to customers throughout the
`
`United States and Canada.
`
`32. While pharmaceutical-grade salt is shipped throughout the United States and
`
`Canada, shipping it from overseas is prohibitively expensive. This is because pharmaceutical-
`
`grade salt may not contain anti-caking agents. Without anti-caking agents, pharmaceutical-grade
`
`salt has a short shelf-life and may be damaged by the time and rigors of ocean-shipping. These
`
`limitations make ocean-shipping cost-prohibitive.
`
`33.
`
`A hypothetical monopolist of pharmaceutical-grade salt in the United States and
`
`Canada could profitably impose a small but significant non-transitory increase in price for
`
`pharmaceutical-grade salt without losing sufficient sales to render the price increase unprofitable.
`
`Accordingly, the relevant geographic market for the purposes of analyzing the effects of the
`
`acquisition on pharmaceutical-grade salt under Section 7 of the Clayton Act, 15 U.S.C. § 18, is
`
`the United States and Canada.
`
`9
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 10 of 18
`
`ii.
`
`Round-Can Table Salt
`
`34.
`
`Competition among round-can table salt suppliers occurs at a national level.
`
`Retailers, many of which are grocery store chains, mass merchandisers, or convenience stores
`
`with large national footprints, purchase round-can table salt for all of their locations at once, and
`
`suppliers ship round-can table salt from coast to coast.
`
`35.
`
`Round-can table salt is not imported from outside the United States. In addition
`
`to being heavy—and therefore expensive to transport—table salt in other countries is typically
`
`sold in bags or cardboard boxes. As such, foreign suppliers of table salt typically lack the
`
`production facilities to produce round cans for the United States market.
`
`36.
`
`A hypothetical monopolist of round-can table salt in the United States could
`
`profitably impose a small but significant non-transitory increase in price for round-can table salt
`
`without losing sufficient sales to render the price increase unprofitable. Accordingly, the
`
`relevant geographic market for the purposes of analyzing the effects of the acquisition on round-
`
`can table salt under Section 7 of the Clayton Act, 15 U.S.C. § 18, is the United States.
`
`iii.
`
`Bulk Evaporated Salt
`
`37.
`
`Bulk evaporated salt is a product that can be produced at a relatively low cost, but
`
`it is heavy and therefore expensive to transport. As a result, customers purchase from nearby
`
`suppliers to minimize shipping costs that can be high relative to the value of the bulk evaporated
`
`salt being purchased.
`
`38.
`
`Both Morton and US Salt—along with only one other competitor—operate bulk
`
`evaporated salt production facilities in upstate New York. All three companies use these
`
`facilities to service customers in the northeastern United States, including Connecticut,
`
`Delaware, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode
`
`10
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 11 of 18
`
`Island, and Vermont. Customers in the northeastern United States can economically procure
`
`bulk evaporated salt from only these three locations. Other more distant bulk evaporated salt
`
`facilities cannot compete successfully on a regular basis for customers in the northeastern United
`
`States because the suppliers are too far away, making transportation costs too great.
`
`39.
`
`A hypothetical monopolist of bulk evaporated salt in the northeastern United
`
`States could profitably impose a small but significant non-transitory increase in price for bulk
`
`evaporated salt without losing sufficient sales to render the price increase unprofitable.
`
`Accordingly, the relevant geographic market for the purposes of analyzing the effects of the
`
`acquisition on bulk evaporated salt under Section 7 of the Clayton Act, 15 U.S.C. § 18, is the
`
`northeastern United States.
`
`V.
`
`ANTICOMPETITIVE EFFECTS
`
`40.
`
`The proposed transaction would lessen competition and harm customers for
`
`pharmaceutical-grade salt in the United States and Canada, round-can table salt in the United
`
`States, and bulk evaporated salt in the northeastern United States by eliminating the substantial
`
`head-to-head competition that currently exists between Morton and US Salt. Customers in each
`
`of these markets would pay higher prices and receive lower quality and service as a result of the
`
`acquisition.
`
`A.
`
`Pharmaceutical-Grade Salt in the United States and Canada
`
`41. Morton and US Salt are the only two suppliers of pharmaceutical-grade salt in the
`
`United States and Canada, with Morton currently having a market share of around 77% and US
`
`Salt a share of around 23%. The acquisition would thus give the combined firm a monopoly in
`
`the sale of pharmaceutical-grade salt in the United States and Canada, leaving pharmaceutical
`
`11
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 12 of 18
`
`companies and other customers without a competitive alternative for this critical ingredient in
`
`dialysis fluid, intravenous saline solution, and other medical products.
`
`42. Morton and US Salt compete to sell pharmaceutical-grade salt on the basis of
`
`quality and surety of supply. This competition has resulted in higher quality, lower prices, and
`
`better customer service. The combination of Morton and US Salt would eliminate this
`
`competition and its future benefits to customers, including pharmaceutical companies. Post-
`
`acquisition, the combined Morton and US Salt likely would have the incentive and ability to
`
`increase prices and offer less favorable contractual terms.
`
`43.
`
`The proposed acquisition, therefore, likely would substantially lessen competition
`
`in the production of pharmaceutical-grade salt in the United States and Canada in violation of
`
`Section 7 of the Clayton Act, 15 U.S.C. § 18.
`
`B.
`
`Round-Can Table Salt in the United States
`
`44. Morton and US Salt are two of the largest table salt suppliers in the United States
`
`and are two of only three suppliers of round-can table salt in the United States. Morton is the
`
`largest supplier of branded round-can table salt in the United States. US Salt is the largest
`
`supplier of private-label round-can table salt—which is made by US Salt but sold under the
`
`brands of retailers and other third-parties—in the United States. US Salt is also the second-
`
`largest supplier of branded round-can table salt, with around six percent of sales.
`
`45.
`
`Today, US Salt’s private-label and branded round-can table salt products compete
`
`directly with Morton’s branded round-can table salt. Together, the combined firm would control
`
`at least 90% of the round-can table salt market in the United States.
`
`46.
`
`The combination of Morton and US Salt would eliminate the head-to-head
`
`competition between Morton and US Salt and leave customers in the United States with only two
`
`12
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 13 of 18
`
`alternatives for round-can table salt in the United States. Post-acquisition, the combined firm
`
`likely would have the incentive and ability to increase prices and offer less favorable contractual
`
`terms.
`
`47. Morton and US Salt compete for sales of round-can table salt on the basis of
`
`quality, price, and contractual terms such as delivery times. This competition has resulted in
`
`higher quality, lower prices, and more reliable delivery. The combination of Morton and US Salt
`
`would eliminate this competition and its future benefits to customers, including grocery chains,
`
`big box stores, and discount stores.
`
`48.
`
` The proposed acquisition, therefore, likely would substantially lessen
`
`competition in the production of round-can table salt in the United States in violation of Section
`
`7 of the Clayton Act, 15 U.S.C. § 18.
`
`C.
`
`49.
`
`Bulk Evaporated Salt in the Northeastern United States
`
`
`
`Three bulk evaporated salt suppliers—Morton, US Salt, and one additional
`
`competitor, each with production facilities in upstate New York—compete for bulk evaporated
`
`salt customers in the northeastern United States. The combination of Morton and US Salt would
`
`eliminate the head-to-head competition between the parties and result in only two remaining
`
`competitors in the region.
`
`50.
`
`Bulk evaporated salt customers in the northeastern United States, including food
`
`processors and chemical manufacturers, have been able to secure lower prices and improved
`
`quality and service—such as more reliable delivery—by threatening to switch between Morton
`
`and US Salt. The elimination of this head-to-head competition would allow a combined Morton
`
`and US Salt to exercise market power to unilaterally increase prices and reduce the quality and
`
`service for bulk evaporated salt customers in the northeastern United States.
`
`13
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 14 of 18
`
`51.
`
`The proposed acquisition, therefore, likely would substantially lessen competition
`
`in the production of bulk evaporated salt in the northeastern United States in violation of Section
`
`7 of the Clayton Act, 15 U.S.C. § 18.
`
`VI.
`
`ENTRY
`
`A.
`
`Difficulty of Entry into Pharmaceutical-Grade Salt in the United States and
`Canada
`
`52.
`
`Entry of new competitors into pharmaceutical-grade salt in the United States
`
`would be difficult and time-consuming and is unlikely to prevent the harm to competition that is
`
`likely to result if the proposed transaction is consummated.
`
`53.
`
`A potential pharmaceutical-grade salt entrant would need to acquire suitable land
`
`that includes a salt deposit of sufficient purity, obtain the permits necessary to construct an
`
`evaporation and processing facility, possess or obtain appropriate financing for a significant
`
`capital expenditure, and then design, construct, and qualify the facility. This process would likely
`
`take several years, at a minimum. No new evaporated salt facility has been constructed in the
`
`United States in over 20 years.
`
`54.
`
`Even if an entrant was able to construct an evaporated salt production facility,
`
`before selling a single grain of pharmaceutical-grade salt, it would need to install and test
`
`additional equipment needed to meet the exacting purity requirements for pharmaceutical-grade
`
`salt. Reputational barriers make entry even more difficult, as customers would be reluctant to
`
`switch to an unproven supplier that could not guarantee access to high-quality pharmaceutical-
`
`grade salt. Thus, entry would not be timely, likely, or sufficient to mitigate the anticompetitive
`
`effects from SCIH’s proposed acquisition of Morton.
`
`B.
`
`55.
`
`Difficulty of Entry into Round-Can Table Salt in the United States
`
`Entry of new competitors into round-can table salt in the United States would be
`
`14
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 15 of 18
`
`difficult and time-consuming and is unlikely to prevent the anticompetitive effects that are likely
`
`to result if the proposed transaction is consummated.
`
`56.
`
`Even though table salt has lower purity requirements than pharmaceutical-grade
`
`salt, a round-can table salt entrant would still need to take all of the steps to construct a facility
`
`that a pharmaceutical-grade salt entrant would, including locating an appropriate salt deposit, and
`
`investing significant time and money to build the facility.
`
`57.
`
`In addition, an entrant in round-can table salt would have to secure a round-can
`
`packaging line. The packaging process for round-can table salt, created decades ago, is based on
`
`technology from that era and has proven to be difficult to replicate in a price-competitive
`
`manner. As a result, potential entrants with access to suitable salt deposits have tried, and failed,
`
`to develop round-can packaging technology in the last five years.
`
`58.
`
`Entry through the construction of a new round-can table salt facility therefore will
`
`not be timely, likely, or sufficient to mitigate the anticompetitive effects of SCIH’s proposed
`
`acquisition of Morton.
`
`C.
`
`Difficulty of Entry into Bulk Evaporated Salt in the Northeastern United
`States
`
`59.
`
`Entry of new competitors into bulk evaporated salt in the northeastern United
`
`States would be difficult and time-consuming and is unlikely to prevent the harm to competition
`
`that is likely to result if the proposed transaction is consummated.
`
`60.
`
`Just as with pharmaceutical-grade salt or round-can table salt, a new entrant in
`
`bulk evaporated salt would need to invest significant time and money to acquire land and
`
`construct an evaporated salt processing facility. Entry into bulk evaporated salt in the
`
`northeastern United States is particularly difficult because this area has limited salt deposits,
`
`which are necessary serve the market.
`
`15
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 16 of 18
`
`61.
`
`Entry through the construction of a new bulk evaporated salt production facility
`
`will therefore not be timely, likely, or sufficient to mitigate the anticompetitive effects from
`
`SCIH’s proposed acquisition of Morton.
`
`VII. VIOLATIONS ALLEGED
`
`62.
`
`SCIH’s proposed acquisition of Morton is likely to substantially lessen
`
`competition in the production and sale of evaporated salt products, including pharmaceutical-
`
`grade salt in the United States and Canada, round-can table salt in the United States, and bulk
`
`evaporated salt in the northeastern United States, in violation of Section 7 of the Clayton Act, 15
`
`U.S.C. § 18.
`
`63.
`
`The acquisition will likely have the following anticompetitive effects, among
`
`others, in the relevant markets:
`
`a.
`
`actual and potential competition between Morton and US Salt will be
`
`eliminated;
`
`b.
`
`c.
`
`competition generally will be substantially lessened; and
`
`prices will likely increase and quality and the level of service will likely
`
`decrease.
`
`VIII. REQUEST FOR RELIEF
`
`64.
`
`The United States requests that this Court:
`
`a.
`
`adjudge and decree SCIH’s acquisition of Morton to be unlawful and in
`
`violation of Section 7 of the Clayton Act, 15 U.S.C. § 18;
`
`b.
`
`preliminarily and permanently enjoin Defendants and all persons acting on
`
`their behalf from consummating the proposed acquisition by SCIH of
`
`Morton or from entering into or carrying out any other contract,
`
`16
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 17 of 18
`
`agreement, plan, or understanding, the effect of which would be to
`
`combine Morton with US Salt;
`
`award the United States the costs for this action; and
`
`grant the United States such other relief as the Court deems just and
`
`c.
`
`d.
`
`
`
`proper.
`
`
`
`17
`
`

`

`Case 1:21-cv-01067-TJK Document 1 Filed 04/19/21 Page 18 of 18
`
`Dated: April 19, 2021
`
`Respectfully submitted,
`
`COUNSEL FOR PLAINTIFF UNITED STATES:
`
` /s/ Richard Powers
`RICHARD POWERS
`Acting Assistant Attorney General
`Antitrust Division
`
` /s/ Kathleen S. O’Neill
`KATHLEEN S. O’NEILL
`Senior Director of Investigation and Litigation
`Antitrust Division
`
` /s/ Katrina Rouse
`KATRINA ROUSE (D.C. Bar #1013035)
`Chief
`Defense, Industrials, and Aerospace Section
`Antitrust Division
`
` /s/ Jay D. Owen
`JAY D. OWEN
`Assistant Chief
`Defense, Industrials, and Aerospace Section
`Antitrust Division
`
`
`
` /s/ Kerrie J. Freeborn
`KERRIE J. FREEBORN* (D.C. Bar #503143)
`BINDI BHAGAT
`JANET BRODY
`GABRIELLA R. MOSKOWITZ (D.C. Bar #1044309)
`REBECCA VALENTINE (D.C. Bar #989607)
`Trial Attorneys
`
`Defense, Industrials, and Aerospace Section
`Antitrust Division
`450 Fifth Street N.W., Suite 8700
`Washington, DC 20530
`Telephone: (202) 476-9160
`Facsimile: (202) 514-9033
`Email: kerrie.freeborn@usdoj.gov
`
`*LEAD ATTORNEY TO BE NOTICED
`
`18
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket